Infinity Pharmaceuticals Inc.  

(Public, NASDAQ:INFI)   Watch this stock  
Find more results for INFI
-0.17 (-1.91%)
Real-time:   1:58PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.51 - 9.25
52 week 7.56 - 18.25
Open 9.00
Vol / Avg. 578,373.00/868,937.00
Mkt cap 440.52M
P/E     -
Div/yield     -
EPS -1.39
Shares 49.19M
Beta 1.11
Inst. own 106%
Nov 4, 2015
Q3 2015 Infinity Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 6, 2015
Infinity Pharmaceuticals Inc 2015 Research & Development Day - 8:00AM EDT - Add to calendar
Sep 16, 2015
Infinity Pharmaceuticals Inc at Morgan Stanley Healthcare Conference
Sep 10, 2015
Infinity Pharmaceuticals Inc at Wells Fargo Healthcare Conference
Sep 9, 2015
Infinity Pharmaceuticals Inc at FBR Healthcare Conference
Aug 11, 2015
Infinity Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Aug 6, 2015
Q2 2015 Infinity Pharmaceuticals Inc Earnings Release
Aug 6, 2015
Q2 2015 Infinity Pharmaceuticals Inc Earnings Call - Webcast
Jul 28, 2015
Infinity Pharmaceuticals Inc at BMO Capital Markets Corporate Access Day
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -787.46% -10.56%
Operating margin -790.82% -4.80%
EBITD margin - -3.73%
Return on average assets -60.62% -5.81%
Return on average equity -147.96% -8.48%
Employees 195 -
CDP Score - -


784 Memorial Dr
CAMBRIDGE, MA 02139-4613
United States - Map
+1-617-4531000 (Phone)
+1-617-4531001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Infinity Pharmaceuticals, Inc. is a biopharmaceutical company that is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target emerging disease pathways for potential applications in oncology. Its most advanced product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies. In addition to duvelisib, the Company seeks to expand its pipeline through internal discovery research program and licensing of potential new product candidates or technologies discovered by third parties. The Company is conducting DUETTS (Duvelisib Trials in Hematologic Malignancies), a worldwide investigation of duvelisib in blood cancers.

Officers and directors

Adelene Q. Perkins Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Lawrence E. Bloch M.D., J.D. Chief Financial Officer, Executive Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Julian Adams Ph.D. President - Research & Development
Age: 60
Bio & Compensation  - Reuters
Winston K C Lam Executive Vice President, General Counsel
Bio & Compensation  - Reuters
Sujay Kango Executive Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters
Vito J. Palombella Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Norman C. Selby Lead Outside Independent Director
Age: 62
Bio & Compensation  - Reuters
Jose Baselga M.D., Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
Jeffrey Berkowitz J.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters